cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Albireo Pharma Inc
4 own
5 watching
Current Price
$0
$0.14
(0.32%)
logo-albo
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
912.55M
52-Week High
52-Week High
44.3998
52-Week Low
52-Week Low
16.02
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization912.55M
icon52-Week High44.3998
icon52-Week Low16.02
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Albireo Pharma Inc do?
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Read More
How much money does Albireo Pharma Inc make?
News & Events about Albireo Pharma Inc.
PR Newswire
12hours ago
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations PR Newswire NEW YORK, Jan. 30, 2023 NEW YORK, Jan. 30, 2023 /PRNewswire/ -- If...
Globe Newswire
2days ago
NEW YORK, Jan. 29, 2023 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CinCor Pharma, Inc. (NASDAQ: CINC)s sale to ...
PR Newswire
3days ago
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger - LBC, ALBO, CINC, LMST PR Newswire NEW YORK, Jan. 27, 2023 NEW YORK, Jan. 27, 2023 /PRNewswire...
Globe Newswire
5days ago
NEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased ...
Zolmax
6days ago
Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) CEO Ronald Harold Wilfred Cooper sold 1,057 shares of the firms stock in a transaction dated Monday, January 23rd. The stock was sold at an average price of $43.80, for a total value of $46,296.60. Following the completion of the sale, the chief ...
Frequently Asked Questions
Frequently Asked Questions
What is Albireo Pharma Inc share price today?
plus_minus_icon
Can Indians buy Albireo Pharma Inc shares?
plus_minus_icon
How can I buy Albireo Pharma Inc shares from India?
plus_minus_icon
Can Fractional shares of Albireo Pharma Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Albireo Pharma Inc stocks?
plus_minus_icon
What is today’s traded volume of Albireo Pharma Inc?
plus_minus_icon
What is today’s market capitalisation of Albireo Pharma Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Albireo Pharma Inc?
plus_minus_icon
What percentage is Albireo Pharma Inc down from its 52-Week High?
plus_minus_icon
What percentage is Albireo Pharma Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$0.14
(0.32%)
logo-albo
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
INHIBRX INC
INHIBRX INC
$26.13
$1.00 (3.98 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$16.29
$0.24 (1.50 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$18.97
$-0.13 (-0.68 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$28.00
$-0.08 (-0.28 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
INHIBRX INC
INHIBRX INC
$26.13
$1.00 (3.98 %)
ARCUTIS BIOTHERAPEUTICS INC
ARCUTIS BIOTHERAPEUTICS INC
$16.29
$0.24 (1.50 %)
Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals Inc
$18.97
$-0.13 (-0.68 %)
Bicycle Therapeutics PLC
Bicycle Therapeutics PLC
$28.00
$-0.08 (-0.28 %)
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00